Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy

Inclusion Criteria:

- 18 years of age or older.

- Clinical diagnosis of ocular hypertension, open-angle glaucoma, or pigment dispersion
glaucoma in both eyes.

- Be on a stable intra-ocular pressure-lowering regimen of prostaglandin fixed
combination (either Xalacom or Ganfort) within 4 weeks prior to the Screening Visit.

- Intra-ocular pressure of between 19 and 35 mmHg at any time of day in at least one
eye.

- Have best corrected visual acuity of 6/60 (20/200 Snellen; 1.0 LogMAR) or better in
each eye.

- Willing to discontinue the use of all other ocular hypotensive medication(s) prior to
receiving the study medication for the entire course of the study.

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Known medical history of allergy, hypersensitivity, or poor tolerance to any
component of DuoTrav® deemed clinically significant in the opinion of the Principal
Investigator.

- Corneal dystrophies in either eye.

- Risk of visual field or visual acuity worsening as a consequence of participation in
the study, in the investigator's best judgment.

- Any disease or condition that would preclude the safe administration of a topical
beta-blocker, present a special risk to the subject, or interfere with optimal
participation in the study.

- Women who are pregnant or lactating.

- Participation in any other investigational study within 30 days prior to the
Screening Visit.

- Other protocol-defined exclusion criteria may apply.